CL2007003054A1 - Peptido de 3 a 40 aminoacidos capaces de regular la exocitosis neuronal; procedimiento de obtencion de dicho peptido; composicion cosmetica y farmaceutica que comprende dicho peptido; uso de dicho peptido para tratar condiciones que requieran regular - Google Patents

Peptido de 3 a 40 aminoacidos capaces de regular la exocitosis neuronal; procedimiento de obtencion de dicho peptido; composicion cosmetica y farmaceutica que comprende dicho peptido; uso de dicho peptido para tratar condiciones que requieran regular

Info

Publication number
CL2007003054A1
CL2007003054A1 CL200703054A CL2007003054A CL2007003054A1 CL 2007003054 A1 CL2007003054 A1 CL 2007003054A1 CL 200703054 A CL200703054 A CL 200703054A CL 2007003054 A CL2007003054 A CL 2007003054A CL 2007003054 A1 CL2007003054 A1 CL 2007003054A1
Authority
CL
Chile
Prior art keywords
peptide
exocitosis
cosmetic
procedure
obtaining
Prior art date
Application number
CL200703054A
Other languages
English (en)
Inventor
Serraima Cristina Carreno
Obiols Berta Ponsati
Montiel Antonio Ferrer
Puche Joan Cebrian
Den Nest Wim Van
Carneado Jimena Fernandez
Domenech Nuria Alminana
Original Assignee
Lipotec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipotec Sa filed Critical Lipotec Sa
Publication of CL2007003054A1 publication Critical patent/CL2007003054A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
CL200703054A 2006-10-25 2007-10-24 Peptido de 3 a 40 aminoacidos capaces de regular la exocitosis neuronal; procedimiento de obtencion de dicho peptido; composicion cosmetica y farmaceutica que comprende dicho peptido; uso de dicho peptido para tratar condiciones que requieran regular CL2007003054A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200602720A ES2322882B1 (es) 2006-10-25 2006-10-25 Peptidos inhibidores de la exocitosis neuronal.

Publications (1)

Publication Number Publication Date
CL2007003054A1 true CL2007003054A1 (es) 2008-03-24

Family

ID=39324166

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200703054A CL2007003054A1 (es) 2006-10-25 2007-10-24 Peptido de 3 a 40 aminoacidos capaces de regular la exocitosis neuronal; procedimiento de obtencion de dicho peptido; composicion cosmetica y farmaceutica que comprende dicho peptido; uso de dicho peptido para tratar condiciones que requieran regular

Country Status (27)

Country Link
US (1) US9464129B2 (es)
EP (1) EP2123673B1 (es)
JP (1) JP5647413B2 (es)
KR (1) KR101606448B1 (es)
CN (1) CN101541831B (es)
AR (1) AR063528A1 (es)
AU (1) AU2007310796B2 (es)
BR (1) BRPI0717376B8 (es)
CA (1) CA2666516C (es)
CL (1) CL2007003054A1 (es)
CY (1) CY1118690T1 (es)
DK (1) DK2123673T3 (es)
ES (2) ES2322882B1 (es)
HR (1) HRP20170378T1 (es)
HU (1) HUE031340T2 (es)
IL (1) IL198191A (es)
LT (1) LT2123673T (es)
MX (1) MX2009004424A (es)
NZ (1) NZ576373A (es)
PL (1) PL2123673T3 (es)
PT (1) PT2123673T (es)
RS (1) RS55755B1 (es)
RU (1) RU2461568C2 (es)
SI (1) SI2123673T1 (es)
TW (1) TWI439291B (es)
WO (1) WO2008049945A1 (es)
ZA (1) ZA200903236B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113929749A (zh) * 2021-11-18 2022-01-14 陕西未来多肽生物科技有限公司 一种十六肽化合物及其制备方法

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019016A (en) 1990-04-10 1991-05-28 Gkn Automotive Inc. Anti-shudder tripod constant velocity universal joint
ES2356883B1 (es) * 2008-07-24 2012-02-22 Bcn Peptides, S.A. Composición para el tratamiento del dolor y/o la inflamación.
US20110305735A1 (en) * 2010-06-09 2011-12-15 Lipotec, S.A. Skin antiaging treatment
FR2961510A1 (fr) * 2010-06-17 2011-12-23 Oreal Utilisation comme agent de traitement de la transpiration humaine ; nouveaux derives d'acide amine ; compositions les contenant
ES2385683B1 (es) * 2010-10-18 2013-10-07 Bcn Peptides, S.A. Composiciones para el tratamiento del dolor y/o la inflamación.
US20130287714A1 (en) * 2010-11-12 2013-10-31 Sven Gohla Cosmetic and/or dermatological preparations containing snow algae extract
EP2802337B2 (en) * 2011-11-07 2021-01-20 Feng Tian Peptide-based compounds as inhibitors of neurotransmitter secretion
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
US10149812B2 (en) 2012-04-13 2018-12-11 Activen Cosmetic composition comprising a muconopeptide
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649984A1 (en) * 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
JP6470678B2 (ja) * 2012-04-13 2019-02-13 ルブリゾル アドバンスド マテリアルズ， インコーポレイテッド ニューロンの開口分泌を阻害する化合物（ｉｉ）
ES2678793T3 (es) 2012-04-13 2018-08-17 Activen Composición cosmética que comprende un muconopéptido
HUE034308T2 (en) 2013-03-21 2018-02-28 Sanofi Aventis Deutschland Preparation of hydantoin-containing peptide products
CN105102427B (zh) 2013-03-21 2018-09-07 赛诺菲-安万特德国有限公司 含有环状酰亚胺的肽产物的合成
MX2016005614A (es) 2013-11-01 2016-12-09 Spherium Biomed S L Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos.
CN103637925B (zh) * 2013-12-03 2015-09-30 广州健坤生物科技有限公司 γ-氨基丁酸(GABA)和一种小肽在化妆品中的联合应用
CN103641888B (zh) * 2013-12-03 2015-08-12 广州健坤生物科技有限公司 一种多功能新型小肽、包含该肽的组合物及其应用
CN103694316B (zh) * 2013-12-31 2015-09-09 杭州华津药业股份有限公司 一种阿基瑞林的制备方法
RU2551276C1 (ru) * 2014-02-03 2015-05-20 Закрытое Акционерное Общество "Фарм-Синтез" Способ получения диацетата трипептида
ES2642916T3 (es) * 2014-06-06 2017-11-20 Galit KLEINER-FISMAN Toxina botulínica para su uso en el tratamiento de la paratonia
EP3212688B1 (en) 2014-10-31 2022-04-13 Lubrizol Advanced Materials, Inc. Thermoplastic polyurethane film for delivery of active agents to skin surfaces
KR101747411B1 (ko) * 2015-04-13 2017-06-14 주식회사 엘지생활건강 신경전달물질을 조절하는 펩타이드의 신경세포 전달용 용해성 미세바늘
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3371238A1 (en) 2015-11-05 2018-09-12 Lubrizol Advanced Materials, Inc. Thermoformable dual network hydrogel compositions
RU2633691C2 (ru) * 2015-12-17 2017-10-16 Федеральное государственное автономное образовательное учреждение высшего образования "Балтийский федеральный университет имени Иммануила Канта" (БФУ им. И. Канта) Способ генетического контроля экзоцитоза на основе генетических конструкций для трансфекции клеток астроглии
KR101895906B1 (ko) * 2016-07-07 2018-10-04 주식회사 한국화장품제조 펩타이드 리포좀을 포함하는 스틱형 화장료 조성물
KR102607079B1 (ko) * 2016-09-09 2023-11-28 주식회사 엘지생활건강 신경세포 투과성이 향상된 신경전달물질 조절 펩타이드
WO2018102508A1 (en) * 2016-11-30 2018-06-07 Lubrizol Advanced Materials, Inc. Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2019004758A2 (ko) * 2017-06-28 2019-01-03 주식회사 엘지생활건강 피부투과 촉진용 펩타이드가 결합된 융합 단백질을 포함하는 피부개선용 화장료 조성물
ES2937382T3 (es) 2018-02-27 2023-03-28 Lipotrue S L Péptidos y composiciones para uso en cosmética y medicina
US12377035B2 (en) 2018-06-13 2025-08-05 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO—A.C.R.A.F. S.p.A. Peptides for inhibiting cholinergic calcitonin gene-related peptide (CGRP) and acetylcholine (ACH) release or inhibiting sensitization-mediated by TRPV1-mediated excitability in sensory neurons and methods of use thereof
CN109021071B (zh) * 2018-08-21 2020-08-04 山西锦波生物医药股份有限公司 肽及其制备方法和用途
ES3032335T3 (en) * 2019-12-04 2025-07-17 Lipotrue S L Peptides and compositions for use in cosmetics and medicine
WO2022162312A1 (fr) * 2021-01-27 2022-08-04 Fabien Schweighoffer Peptides et leurs utilisations
CN113512092A (zh) * 2021-06-28 2021-10-19 陕西未来多肽生物科技有限公司 多肽纳米杂化物及其用途
CN113402586A (zh) * 2021-06-28 2021-09-17 陕西未来多肽生物科技有限公司 一种多肽及其应用
CN114933634B (zh) * 2021-11-18 2024-08-09 陕西未来多肽生物科技有限公司 一种乙酰基十六肽的合成方法
EP4230638A1 (en) 2022-02-16 2023-08-23 Lipotrue, S.L. Peptides and compositions for use in cosmetics
WO2023155881A1 (en) * 2022-02-18 2023-08-24 Tsinghua University Methods for regulating secretion via migrasomes
WO2023184114A1 (zh) 2022-03-28 2023-10-05 深圳市维琪科技股份有限公司 一种多肽及其美容组合物或药用组合物和用途
CN120302959A (zh) * 2022-07-13 2025-07-11 欧莱雅 修饰肽、组合物、抑制肌肉细胞收缩的方法、改善皮肤的方法和修饰肽的用途
CN118063547A (zh) * 2024-03-01 2024-05-24 深圳市维琪科技股份有限公司 环八肽及其组合物和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83398A0 (en) * 1986-08-07 1987-12-31 Fidia Spa Novel neuronotrophic factor
IL97557A0 (en) * 1990-03-14 1992-06-21 Fidia Spa Process for the isolation and expression of the human ciliary neuronotrophic factor by recombinant dna technology
AU2334897A (en) 1996-03-18 1997-10-10 Regents Of The University Of California, The Peptide inhibitors of neurotransmitter secretion by neuronal cells
ES2160485B1 (es) * 1999-04-23 2002-05-16 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
KR101116528B1 (ko) * 2003-05-08 2012-02-28 디에스엠 아이피 어셋츠 비.브이. 피부구조를 향상시키는 트리펩타이드 및 그 유도체의 미용용도
ES2293753B1 (es) * 2004-04-28 2009-03-16 Lipotec, S.A. Uso de peptidos xikvav en preparacion de composiciones cosmeticas para mejorar la firmeza de la piel mediante el aumento de la adhesion celular.
SG160358A1 (en) * 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of an oligopeptide
ES2259928B1 (es) * 2005-04-08 2007-11-01 Lipotec, S.A. Composicion cosmetica o dermofarmaceutica que comprende peptidos derivados de encefalinas para reducir y/o eliminar arrugas faciales.
US7807625B2 (en) * 2006-01-18 2010-10-05 Grant Industries, Inc Anti-wrinkle composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113929749A (zh) * 2021-11-18 2022-01-14 陕西未来多肽生物科技有限公司 一种十六肽化合物及其制备方法

Also Published As

Publication number Publication date
JP5647413B2 (ja) 2014-12-24
ES2322882A1 (es) 2009-06-30
PL2123673T3 (pl) 2017-06-30
NZ576373A (en) 2011-11-25
TW200833365A (en) 2008-08-16
AU2007310796A1 (en) 2008-05-02
HK1132999A1 (en) 2010-03-12
EP2123673A1 (en) 2009-11-25
LT2123673T (lt) 2017-03-27
PT2123673T (pt) 2017-03-01
SI2123673T1 (sl) 2017-07-31
RU2461568C2 (ru) 2012-09-20
CA2666516C (en) 2017-06-13
BRPI0717376B1 (pt) 2018-07-24
CN101541831B (zh) 2015-04-01
KR101606448B1 (ko) 2016-03-25
AU2007310796B2 (en) 2013-10-10
AR063528A1 (es) 2009-01-28
IL198191A0 (en) 2011-08-01
KR20090090307A (ko) 2009-08-25
RU2009114804A (ru) 2010-11-27
ES2638286T3 (es) 2017-10-19
HRP20170378T1 (hr) 2017-05-05
EP2123673A4 (en) 2011-01-12
CY1118690T1 (el) 2017-07-12
CA2666516A1 (en) 2008-05-02
TWI439291B (zh) 2014-06-01
JP2010507632A (ja) 2010-03-11
RS55755B1 (sr) 2017-07-31
BRPI0717376B8 (pt) 2021-05-25
HUE031340T2 (en) 2017-07-28
DK2123673T3 (en) 2017-03-20
IL198191A (en) 2016-07-31
US9464129B2 (en) 2016-10-11
US20100021510A1 (en) 2010-01-28
WO2008049945A1 (es) 2008-05-02
BRPI0717376A2 (pt) 2013-10-29
CN101541831A (zh) 2009-09-23
EP2123673B1 (en) 2016-12-07
MX2009004424A (es) 2009-05-11
ZA200903236B (en) 2010-07-28
ES2322882B1 (es) 2010-04-22

Similar Documents

Publication Publication Date Title
CL2007002502A1 (es) Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
BRPI0906064A2 (pt) "peptídeo, processo para obtenção de um peptídeo de fórmula geral (i), composição cosmética ou farmacêutica e uso de um peptídeo de fórmula geral (i)"
SV2009003187A (es) 4-[4-({[4-cloro-3-(trifluorometil) fenil] carbamoil} amino)-3-fluorofenoxi]-n-metilpiridina-2-carboxamida monohidrato
BRPI0819703A2 (pt) Uso de inibidores de proteína tirosina fosfatase e hormônio de crescimento humano, uso de igf1 e um inibidor de proteína tirosina fosfatase e composição de combinação farmacêutica para o tratamento de atrofia muscular e distúrbios relacionados
CL2008000066A1 (es) Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
PL2803663T3 (pl) Inhibitory ludzkiej białkowej fosfatazy tyrozynowej i ich zastosowanie farmaceutyczne
EP2451439A4 (en) COMPOSITION COMPRISING BIOACTIVE AMINO ACIDS AND / OR PEPTIDES AND FISH OIL IN A WATER-OIL STABLE EMULSION, AND THE USE OF SAID COMPOSITION AS A FUNCTIONAL OR THERAPEUTIC COMPOSITION
BRPI0811180A2 (pt) Uso de probióticos ou uma mistura dos mesmos para a preparação de composição farmacêutica utilizável em um ambiente pré e/ou pós-cirúrgico.
BRPI0612274A2 (pt) lipase, uso de uma lipase ou uma mistura de lípases, composição farmacêutica, e, método para o tratamento de uma doença
BRPI0700678A (pt) método para aperfeiçoar comportamentos de sono
CL2009001484A1 (es) Sal glicinato de metformina; composición farmacéutica que comprende la sal; y su uso para tratar la hiperglicemia.
BRPI0722093A2 (pt) Composições e usos para um polipeptídeo de alfa-amilase da espécie bacillus 195
PT2341142E (pt) Péptido wt1 restringido a hla-a*1101 e composição farmacêutica compreendendo o mesmo
CL2007003805A1 (es) Forma cristalina del compuesto 3-{[5-(acetidin-1-ilcarbonil)piracin-2-il]oxi}-5-[(1-metiletil)oxi]-n-1h-pirazol-3-ilbenzamida; procedimiento de preparacion; composicion farmaceutica que comprende a dicha forma; y uso para el tratamiento de la diabete
ITMI20041567A1 (it) "derivati n-acilati di acidi bicarbossilici con amminoacidi e con idrolizzati proteici vegetali e loro applicazione in prodotti cosmetici, dermofarmaceutici e farmaceutici"
BR112014009788A2 (pt) cabeça para aspersão de um produto, método para o tratamento cosmético de substâncias queratinosas humanas, uso de uma cabeça de aspersão e kit cosmético
BRPI0906311A2 (pt) "uso de um muramil dipeptídeo reticulado em uma micropartícula e composição farmacêutica dotada de atividade neoplásica"
CL2008000887A1 (es) Compuestos derivados de 3-hidroxi-1h-pirimidin-4-ona o 3-hidroxi-piran-4-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad neurodegenerativa causada por la presencia de
CL2007002329A1 (es) Compuestos derivados de 5,6-bisaril-2-piridin carboxamida, inhibidores de urotensina ii; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar y/o prevenir insuficiencia cardiaca congestiva, is
BRPI0616982B8 (pt) uso de oligouronato, composição farmacêutica inalável e aplicador de spray
MX2012001686A (es) Complejo aclarador de la piel, uso del complejo, composicion cosmetica o farmaceutica que comprende el complejo y metodo para su aplicacion.
BR112013019513A2 (pt) métodos para o tratamento de úlceras diabéticas do pé
EP2229138A4 (en) TOPICAL COMPOSITIONS COMPRISING NON-PROTEOGENIC AMINO ACIDS AND METHODS OF TREATING THE SKIN
EP1430933A3 (de) Kosmetische und pharmazeutische Zusammensetzungen enthaltend Steroidsulfatase-Inhibitoren und deren Verwendung zur Verminderung von Haarausfall
CL2008000573A1 (es) Forma cristalina de la sal 3-endo-(8-[2-[ciclohexilmetil-((s)-2,3-dihidroxi-propionil) amino]etil]-8aza-biciclo[3,2,1] oct-3-il)benzamida; proceso para la preparacion de dicha sal; composicion farmaceutica que comprende a dicha sal; y su uso en disfu